SpinChip Diagnostics is a medical device company who is developing a game changing and proprietary platform for in vitro diagnostics point of care analyses. The platform will make it possible to perform a broader range of analyses using one platform and to transfer analyses from central laboratories to point of care without loss in quality. All analyses are performed within a few minutes based on a fraction of a droplet of blood and at a unit cost significantly lower than other point of care platforms.
Carnegie congratulates Chair Åse Aulie Michelet, CEO Morten Jurs, CSO Stig Morten Borch, the shareholders and the rest of the SpinChip team with the successful transaction. We look forward to continuing our support of SpinChip going forward.